Resources by service
Achieving faster formulation of solid oral dosage forms for first-in-human supplies using drug in capsule approach
The pharmaceutical industry is increasingly looking for approaches that shorten drug development timelines and save on cost, especially virtual biotech companies who rely heavily on key milestone payments. Consequently, it is imperative that new chemical entities can be quickly manufactured into clinical drug products.
Across the industry there are two principle approaches to formulation development of solid oral dosage forms for First-In-Human (FIH) studies, namely the “commercial formulation approach” which produces a clinical formulation that will bear resemblance to commercially acceptable formulations and the “exploratory formulation approach” which favours the use of the simplest possible formulation such as powder-in-capsule (PIC) / drug-in-capsule.
This whitepaper explores both of these two principle approaches and is broadly broken-down into two areas; the direct and indirect cost savings associated with the “exploratory formulation approach”, and how systems such as the Xcelodose® 600S mitigate against some of the risks associated with using the “commercial formulation approach” in early development.
*By submitting your information you acknowledge that you have read the privacy statement and you consent to our processing the data in accordance with that privacy statement. We may, from time to time, send you material relevant to your interests. If you change your mind at any time about wishing to receive material from us, you can send an email to firstname.lastname@example.org. Every email we send you will also include an unsubscribe link so you can unsubscribe from our marketing list.